Samsca
Designed to target fluid balance abnormalities by antagonizing vasopressin receptors to alleviate symptoms associated with hyponatraemia.
Strengths: 15 · 30mg
Where to Check Availability
Medicine details
- Therapeutic class
Vasopressin Receptor Antagonist
- Pharmacological class
Selective V2 Receptor Antagonist
- Contraindications
hypersensitivity to tolvaptan; anuria; hypovolaemic hyponatraemia
- Minor side effects
thirst; polyuria; dry mouth; nausea
- Moderate side effects
hypernatraemia; diarrhoea; constipation; increased blood creatinine
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Otsuka Pharmaceutical
- Onset Time
2–4 hours
- Duration
12–24 hours
- Storage instructions
Store at room temperature.
- Drug interactions
CYP3A4 inhibitors; grapefruit
- Age restrictions
Adults only.
- Pregnancy and breastfeeding
Pregnancy: Use only if clearly necessary. Breastfeeding: Not recommended.
Serious side effects
severe hepatic injury — requires immediate medical attention; osmotic demyelination syndrome — requires immediate medical attention
Patient summary
Designed to target fluid balance abnormalities by antagonizing vasopressin receptors to alleviate symptoms associated with hyponatraemia.
Mechanism of action
Tolvaptan binds specifically to vasopressin V2 receptors in the kidney, which inhibits free water reabsorption and induces aquaresis, effectively managing water retention and serum sodium levels.
Samsca
Designed to target fluid balance abnormalities by antagonizing vasopressin receptors to alleviate symptoms associated with hyponatraemia.
Editorial Notes
- Active ingredient(s): Tolvaptan
- Listed indication(s): Hyponatraemia, Autosomal Dominant Polycystic Kidney Disease
Usually available as
- 20 tablets - 15 mg1026-15-mg-12927
- 20 tablets - 30 mg1026-30-mg-12935